Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn's Disease: A Post Hoc Analysis of the IM-UNITI Trial.

Emily C L WongJohn K MarshallWalter ReinischNeeraj Narula

Published in: Inflammatory bowel diseases (2022)

Although BMI impacts ustekinumab drug levels, there was no impact of BMI on clinical efficacy. Further studies of the pharmacodynamic effects of ustekinumab in patients with high BMI are needed.

Keyphrases

body mass index
weight gain
physical activity
clinical trial
study protocol
phase iii
phase ii
case control